ARDS Market Size
The global Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at USD 2.16 billion in 2025 and is projected to reach USD 3.66 billion by 2035, expanding at a CAGR of 5.8% during the forecast period from 2026 to 2035. The market is gaining importance as severe respiratory complications associated with pneumonia, sepsis, trauma, and other critical illnesses continue to drive demand for intensive-care interventions. Growing adoption of lung-protective ventilation, ECMO, oxygen therapies, and advanced critical-care monitoring is creating opportunities for pharmaceutical and medical-device companies.
Acute respiratory distress syndrome is a severe and life-threatening condition characterized by widespread inflammation in the lungs that leads to respiratory failure. It is marked by the sudden onset of severe respiratory symptoms and a significant decrease in oxygen levels in the blood.
Acute respiratory distress syndrome typically develops within a few hours to a few days after the onset of an underlying injury or illness. The mechanism involves an inflammatory response that damages the delicate lung tissue. This inflammation causes increased permeability of the alveolar-capillary membrane, allowing fluid to leak into the alveoli.
ARDS Market Scope
| Metric | Details |
| Market Size in 2025 | USD 2.16 billion |
| Market Size by 2035 | USD 3.66 billion |
| CAGR | 5.80% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| 2023 Market Size | USD 1.93 billion |
| 2024 Market Size | USD 2.04 billion |
| 2026 Market Size | USD 2.29 billion |
| Segments Covered | Treatment, Route of Administration, Sales Channel |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
For more details on this report – Request for Sample
ARDS Market Dynamics
Increasing incidence of sepsis
The increasing prevalence of sepsis acts as a significant driver for market growth. Sepsis triggers a systemic inflammatory response as the body attempts to fight the infection. This response can become dysregulated which leads to widespread inflammation throughout the lungs.
For instance, according to the World Health Organisation Report 2023, there were 48.9 million cases and 11 million sepsis-related deaths worldwide which accounted for almost 20% of all global deaths. Also, almost half of all global sepsis cases occurred among children, with an estimated 20 million cases and 2.9 million global deaths in children under 5 years of age.
Additionally, according to the National Institute of Health Report 2022, nine observational studies involving 324,020 Chinese patients (9,587 patients with sepsis) were analyzed. Four hospital-wide studies involving 301,272 patients showed pooled prevalence and mortality of 3.8% and 26% respectively. Hence, the increasing incidence of sepsis can lead to the main cause of acute respiratory distress syndrome.
Furthermore, significant growth drivers such as the increasing awareness regarding ARDS, rising geriatric population, and increasing acute lung injuries are expected to drive the market in the forecast period.
Lack of specific therapies
The lack of specific therapies for Acute Respiratory Distress Syndrome (ARDS) is a significant challenge. ARDS is a syndrome with diverse causes, including sepsis, pneumonia, trauma, and others. The underlying pathophysiology can vary which leads to differences in the response to treatment. Also, the limited understanding hinders the development of targeted therapies aimed at specific molecular pathways. Thus, the above factors can hamper the market growth.
ARDS Market Segment Analysis
The global acute respiratory distress syndrome treatment market is segmented based on treatment, route of administration, sales channel and region.
The corticosteroids segment accounted for approximately 56.8% of the market share
The corticosteroids segment is expected to hold the largest market share over the period forecast. Acute respiratory distress syndrome involves an inflammatory response in the lungs. Corticosteroids, with their potent anti-inflammatory effects can theoretically help in modulating the excessive inflammation associated with ARDS.
The timing of corticosteroid administration is crucial and the early administration of corticosteroids during the inflammatory phase can have different implications compared to late administration in the fibroproliferative phase.
Methylprednisolone and dexamethasone are both corticosteroids that have been studied in the context of Acute Respiratory Distress Syndrome (ARDS). These medications belong to the class of glucocorticoids and have anti-inflammatory and immunosuppressive properties. The use of methylprednisolone in ARDS has been studied in clinical trials and has been associated with improved oxygenation and a reduction in markers of inflammation.
ARDS Market Geographical Analysis
North America is expected to hold a significant position in the global acute respiratory distress syndrome treatment market share
The global acute respiratory distress syndrome treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East and Africa.
North America has maintained a significant market proportion due to factors such as the increasing prevalence of ARDS, clinical trials, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, according to the National Institute of Health Report 2023, the incidence of ARDS in the United States ranges from 64.2 to 78.9 cases per 100,000 person-years. Twenty-five percent of ARDS cases are initially classified as mild, and 75% as moderate or severe.
Additionally, in July 2023, Aqualung Therapeutics received FDA Clearance to proceed with the P2A PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) patients. Hence, due to the above factors, it is expected to drive the region’s growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global acute respiratory distress syndrome treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, drug launches, and consultations worldwide. With the outbreak of the pandemic, many treatment centers faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the acute respiratory distress syndrome treatment market was moderately affected over the forecast period.
ARDS Market Competitive Landscape
The major global players in the market include AbbVie Inc., Pfizer Inc., Par Pharmaceutical Inc., Merit Pharmaceutical, Narang Medical Limited, Beijing Aeonmed Co. Ltd., Shenzhen Mindray Bio-Medical Electronic Co. Ltd, Medtronic Plc., Drägerwerk AG & Co. KGaA and ONY Biotech Inc among others.
Key Developments
July 2026: BioAegis Therapeutics continued its global Phase II development program for BTI-203 (recombinant human plasma gelsolin) in moderate-to-severe ARDS caused by pneumonia and other infections. The multicenter study is evaluating the therapy in addition to standard of care across 13 countries and 75 clinical sites, reflecting increasing international development activity for host-directed ARDS therapies.
June 2026: Direct Biologics advanced the clinical development of ExoFlo, an extracellular-vesicle-based investigational therapy for ARDS. The program continues to evaluate regenerative treatment approaches designed to address inflammation and lung injury, supporting the expansion of cell-free biologic therapies in the North American ARDS treatment pipeline.
May 2026: ClinicalTrials.gov listed the JUST BREATHE Phase II program evaluating host-directed therapeutics for ARDS, reflecting continued efforts to develop treatments that target the underlying inflammatory and immune mechanisms of acute lung injury rather than relying solely on supportive respiratory care.
April 2026: Medregen continued development of MRG-001, an investigational cell-based therapy being evaluated in the SUMMIT Phase IIa study for ARDS. The program is designed to assess the safety and efficacy of MRG-001 compared with placebo, supporting growing interest in regenerative medicine approaches for severe acute lung injury.
March 2026: The ARDS clinical pipeline continued to expand, with more than 50 companies developing investigational therapies spanning mechanisms such as complement inhibition, MAPK14 inhibition, and eNAMPT inhibition. This diversification reflects increasing research focus on targeted pharmacological interventions for ARDS across North America, Europe, and other major clinical-development markets.
Why Purchase the Report?
- To visualize the global acute respiratory distress syndrome treatment market segmentation based on treatment, route of administration, sales channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global acute respiratory distress syndrome treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global acute respiratory distress syndrome treatment market report would provide approximately 61 tables, 58 figures, and 185 Pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
